NeuroVive announces Arbutus Biopharma’s notice of termination
Lund, Sweden, July 6, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announces that Arbutus Biopharma (formerly OnCore Biopharma, Inc.) has given NeuroVive a purported notice of termination of the license agreement signed in 2014, related to the development and commercialization of NeuroVive’s compound NVP018 for oral treatment of HBV. Arbutus’ notice, which NeuroVive questions on several grounds and in respect of which NeuroVive has reserved its rights, is a consequence of Arbutus’s decision to discontinue development of